Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy

Raphaëlle Delattre(Centre National de la Recherche Scientifique), Laurent Debarbieux(Centre National de la Recherche Scientifique), Jean-Damien Ricard(Inserm), Baptiste Gaborieau(Délégation Paris 5), Rokhaya Kane(Centre National de la Recherche Scientifique), Jérémie Guedj(Inserm), Nicolas Dufour(Centre Hospitalier René-Dubos), Feyrouz Haddad(Centre National de la Recherche Scientifique), Thu-Thuy Nguyen(Inserm), Jérémy Seurat(Inserm)
Cell Reports
May 1, 2022
10.1016/j.celrep.2022.110825
Cited by 46

Related Papers

Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
|Science|2020|382
Effect of Postextubation High-Flow Nasal Oxygen With Noninvasive Ventilation vs High-Flow Nasal Oxygen Alone on Reintubation Among Patients at High Risk of Extubation Failure
|JAMA|2019|350
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
|Pharmaceutical Research|2010|298
Prediction of strain level phage–host interactions across the Escherichia genus using only genomic information
|Nature Microbiology|2024|119